Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Harvard Apparatus Regenerative TechnologyHRGN 14 Cyclically Adjusted PB Ratio is 1.82 as of Aug. 14, 2026, which is 112% above its 10-year median of 0.86. GuruFocus rates HRGN with a GF Score™ of 14/100. The stock has 2 warning signs investors should review. Among 1,397 Consumer Packaged Goods companies, Harvard Apparatus Regenerative Technology ranks worse than 50.82% on this metric.
HRGN's Cyclically Adjusted PB Ratio is ranked worse than 50.82% of 1397
companies
in the Consumer Packaged Goods industry
Industry Median: 1.26
vs HRGN: 1.29
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Harvard Apparatus Regenerative Technology's adjusted book value per share data for the three months ended in Mar. 2026 was $0.005. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.77 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Harvard Apparatus Regenerative Technology (OTCPK:HRGN) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Harvard Apparatus Regenerative Technology Cyclically Adjusted PB Ratio Related Terms
Harvard Apparatus Regenerative Technology Cyclically Adjusted PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harvard Apparatus Regenerative Technology Cyclically Adjusted PB Ratio Chart
Harvard Apparatus Regenerative Technology Annual Data
HRGN vs JVA, BRLS, LIMX: Cyclically Adjusted PB Ratio Comparison
For the Packaged Foods subindustry, Harvard Apparatus Regenerative Technology's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harvard Apparatus Regenerative Technology Cyclically Adjusted PB Ratio vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Harvard Apparatus Regenerative Technology's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Harvard Apparatus Regenerative Technology's Cyclically Adjusted PB Ratio falls into.
Harvard Apparatus Regenerative Technology Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 1.82 mean?
Harvard Apparatus Regenerative Technology (HRGN) has a Cyclically Adjusted PB Ratio of 1.82 as of Aug. 14, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Harvard Apparatus Regenerative Technology and its competitors. This is 112% above median its historical median of 0.86. Over the past decade, Harvard Apparatus Regenerative Technology's Cyclically Adjusted PB Ratio has ranged from 0.46 to 2.18. According to the industry distribution chart, Harvard Apparatus Regenerative Technology ranks #710 out of 1397 companies in the Consumer Packaged Goods industry, placing it in the top 50.8%.
Is Harvard Apparatus Regenerative Technology's Cyclically Adjusted PB Ratio too high?
Harvard Apparatus Regenerative Technology's current Cyclically Adjusted PB Ratio of 1.82 is 112% above median its 10-year median of 0.86. Over the past 10 years, this metric has ranged from a low of 0.46 to a high of 2.18. The Consumer Packaged Goods industry median Cyclically Adjusted PB Ratio is 1.26. Harvard Apparatus Regenerative Technology's value of 1.82 is 44.4% above this industry median. Based on the distribution chart, Harvard Apparatus Regenerative Technology ranks #710 out of 1397 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, Harvard Apparatus Regenerative Technology has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Harvard Apparatus Regenerative Technology's Cyclically Adjusted PB Ratio compare to JVA and BRLS?
According to the Consumer Packaged Goods industry distribution chart, Harvard Apparatus Regenerative Technology ranks #710 out of 1397 companies for Cyclically Adjusted PB Ratio. This places Harvard Apparatus Regenerative Technology in the lower half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.26. Harvard Apparatus Regenerative Technology's value of 1.82 is 44.4% above this benchmark. Historically, Harvard Apparatus Regenerative Technology's own Cyclically Adjusted PB Ratio has ranged from 0.46 to 2.18 over the past decade. While the company's 10-year median is 0.86 vs. the industry median of 1.26, Harvard Apparatus Regenerative Technology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Consumer Packaged Goods company?
The median Cyclically Adjusted PB Ratio among Consumer Packaged Goods companies is 1.26, based on 1,397 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Harvard Apparatus Regenerative Technology's current Cyclically Adjusted PB Ratio of 1.82 is 44.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Harvard Apparatus Regenerative Technology and its competitors. For the Consumer Packaged Goods industry, the median Cyclically Adjusted PB Ratio is 1.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harvard Apparatus Regenerative Technology's current Cyclically Adjusted PB Ratio is 1.82, which is 112% above median its own 10-year median of 0.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harvard Apparatus Regenerative Technology stock overvalued right now?
Harvard Apparatus Regenerative Technology (HRGN) has a current Cyclically Adjusted PB Ratio of 1.82. The current Cyclically Adjusted PB Ratio is 1.82, which is 112% above median its 10-year median of 0.86 and 44.4% above the Consumer Packaged Goods industry median of 1.26. Harvard Apparatus Regenerative Technology's overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Harvard Apparatus Regenerative Technology (HRGN), the current Cyclically Adjusted PB Ratio is 1.82 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Harvard Apparatus Regenerative Technology is a clinical-stage biotechnology company focused on the development of regenerative medicine treatments for disorders of the gastrointestinal system and other organs that result from cancer, trauma, or birth defects. Its technology is based on a proprietary cell-therapy platform that uses a patient's own stem cells to regenerate and restore function to damaged organs. The Company has two operating and reportable segments: Regenerative Biotech, focused on the development of regenerative medicine treatments with operations currently in the United States, and Consumer Health Products relating to consumer health products with operations currently in Asia.
14GF Score
Get the complete analysis for HRGN
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HRGN has been successfully added to your 
